Table 2 Patient characteristics
From: Effect of pirfenidone on wound healing in lung transplant patients
Variable | Pirfenidone n = 17 | Control n = 13 |
|---|---|---|
Demographics | ||
Mean age, years (range) | 67 (60-77) | 65 (58-73) |
Female sex | 2 (11.8) | 3 (23.1) |
Mean BMI, kg/m2 (range) | 25.7 (20.45-33.5) | 26.9 (20.2-34.6) |
ECMO as bridge to transplant | 2 (12) | 1 (7.7) |
Inpatient prior to transplant | 6 (35.3) | 4 (30.8) |
Unilateral lung transplant | 3 (17.6) | 0 (0) |
Mean LAS (range) | 46 (32-90) | 57 (33-94) |
Pre-transplant steroid use | 8 | 7 |
Prednisone ≤ 10 mg daily | 10 (58.8) | 6 (46.2) |
Prednisone > 10 mg daily | 1 (5.9) | 1 (7.7) |
Baseline laboratory values | ||
Glucose > 180 mg/dL | 0 (0) | 0 (0) |
ALT > 55 units/L | 1 (5.9) | 0 (0) |
AST > 34 units/L | 0 (0) | 1 (7.7) |
AlkPhos > 150 units/L | 0 (0) | 0 (0) |
Albumin < 3.5 g/dL | 2 (11.8) | 3 (23.1) |
Bilirubin > 1.2 mg/dL | 0 (0) | 1 (7.7) |
Creatinine > 1.25 mg/dL | 0 (0) | 0 (0) |
Phosphorous < 2.4 mg/dL | 0 (0) | 2 (15.4) |
Immunosuppressant therapy post-transplant | ||
High-dose steroid + taper | 17 (100) | 13 (100) |
Basiliximab | 11 (64.7) | 8 (61.5) |
Tacrolimus | 17 (100) | 13 (100) |
Cyclosporine | 0 (0) | 2 (15.4) |
Mycophenolate | 17 (100) | 12 (92.3) |
Rituximab | 4 (23.5) | 4 (30.8) |
Antithymocyte globulin | 2 (11.8) | 0 (0) |
Azathioprine | 0 (0) | 1 (7.7) |